This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.
Top Ranked Growth Stocks to Buy for October 24th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, October 24th:
Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.
PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid
by Zacks Equity Research
PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.
Amedisys (AMED) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys to Buy Compassionate Care Hospice, Share Price Down
by Zacks Equity Research
Amedisys (AMED) adopts initiatives to boost hospice business. It expects to become the third-largest hospice provider in America with the latest buyout.
Quest Diagnostics Boosts Health & Wellness, Acquires Provant
by Zacks Equity Research
Quest Diagnostics' (DGX) Provant Health acquisition is in line with its 'accelerate growth' strategy.
QIAGEN Introduces New RNA-seq Library Preparation Solutions
by Zacks Equity Research
QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.
Walgreens (WBA) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division witnesses comparable prescription growth and benefits from a strong retail prescription market.
BioScrip Grows on CORE Plan, Reimbursement Issues Persist
by Zacks Equity Research
BioScrip (BIOS) progresses well on the back of its new multi-faceted CORE plan to improve its financial position.
Genomic Health's Test Gets Favored by New NCCN Guidelines
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with the development of Oncotype DX Breast Recurrence Score test.
Here's Why You Should Invest in Boston Scientific Stock Now
by Zacks Equity Research
Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.
Edwards Begins US CENTERA Study, Reintroduces Valve in Europe
by Zacks Equity Research
Edwards (EW) is recommencing commercial introduction of CENTERA valve in Europe after making certain minor modification to CENTERA's delivery system.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) continues to see increasing private coverage for the Oncotype DX GPS test.
GNC Holdings E-Commerce Business Solid, Competition Rife
by Zacks Equity Research
GNC Holdings (GNC) continues to register strong performance in e-commerce business. A competitive landscape is a threat.
CVS Health's Aetna Deal Imminent, PBM Selling Season Strong
by Zacks Equity Research
CVS Health (CVS) is steadily approaching the Aetna deal wrap-up. Per the company, this significant buyout might alter the whole Healthcare landscape in the United States.
Teleflex's Latest Essential Medical Buyout to Broaden Suite
by Zacks Equity Research
Teleflex (TFX) acquires Essential Medical to strengthen hold in the high-potential structural heart and endovascular aneurysm repair markets.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in select international markets bode well for Tandem Diabetes (TNDM).
Here's Why You Should Invest in Henry Schein (HSIC) Stock
by Zacks Equity Research
Henry Schein's (HSIC) strategy to extend digital dentistry globally is encouraging. Recent acquisitions will strengthen its foothold in the high-potential dental market.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
by Zacks Equity Research
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
Genomic Health's New Data on Oncotype DX GPS to Boost Uptake
by Zacks Equity Research
Genomic Health (GHDX) continues to see positive developments within the U.S. prostate cancer test business.
Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.
New Strong Buy Stocks for October 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Boston Scientific Grows on Acquisitions, Product Launches
by Zacks Equity Research
Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.
Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm
by Zacks Equity Research
Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.